Drug Profile
Meningococcal vaccine groups A C Y W-135 conjugate - Beijing Minhai Biotechnology
Alternative Names: 4-valent Meningococcal Conjugate Vaccine - Beijing Minhai BiotechnologyLatest Information Update: 26 Aug 2019
Price :
$50
*
At a glance
- Originator Beijing Minhai Biotechnology
- Class Conjugate vaccines; Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
Most Recent Events
- 26 Aug 2019 Discontinued - Phase-III for Meningococcal group A infections (In children, In infants, Prevention) in China (IM)
- 26 Aug 2019 Discontinued - Phase-III for Meningococcal group C infections (In children, In infants, Prevention) in China (IM)
- 26 Aug 2019 Discontinued - Phase-III for Meningococcal group W-135 infections (In children, In infants, Prevention) in China (IM)